270 related articles for article (PubMed ID: 10606253)
1. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
2. Fluoropyrimidine resistance in colon cancer.
Gorlick R; Banerjee D
Expert Rev Anticancer Ther; 2002 Aug; 2(4):409-16. PubMed ID: 12647984
[TBL] [Abstract][Full Text] [Related]
3. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials referral resource. Clinical trials with tomudex.
Sorensen JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
[No Abstract] [Full Text] [Related]
5. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
6. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
7. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
9. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
12. Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 2000 Jul; 72(1):112-4. PubMed ID: 10979221
[No Abstract] [Full Text] [Related]
13. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors.
Rooney PH; Stevenson DA; Marsh S; Johnston PG; Haites NE; Cassidy J; McLeod HL
Cancer Res; 1998 Nov; 58(22):5042-5. PubMed ID: 9823306
[TBL] [Abstract][Full Text] [Related]
14. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
16. [Raltitrexed in colorectal cancer].
Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
[No Abstract] [Full Text] [Related]
17. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
18. Raltitrexed in colorectal cancer.
Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
[TBL] [Abstract][Full Text] [Related]
19. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz RM; Patel VF; Worzalla JF; Shih C
Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Wang W; Marsh S; Cassidy J; McLeod HL
Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]